GLP-1 series
Module 4 · Safety
Managing Adverse Effects & Safety Considerations
The gastrointestinal signal that dominates, the rare-but-serious risks, why stepwise escalation limits harm, and what to monitor.
8 slides · 12 minutes
Video coming soon
12-minute recorded module
What this module covers
- 01The GLP-1 landscape and why safety questions arrive
- 02Gastrointestinal effects: the dominant signal
- 03Serious but rare risks: where real exposure sits
- 04Dose escalation as the core safety mechanism
- 05Monitoring and contraindications
- 06What it means for risk assessment
Key takeaways
Most adverse effects are GI, dose-related and transient.
Gradual titration is the single most effective harm-reduction step.
Contraindication screening must be documented, not assumed.
Continue the series
Module 1
GLP-1–Based Therapies in Cardio-Oncology
Module 2
GLP-1 Receptor Agonist Therapy: The Complete Briefing
Module 3
Obesity, Cardiometabolic Health & GLP-1 Therapies
Educational information only. It does not replace advice from your oncology or primary care team, and no treatment decision should be made from this module alone.